Prestige Consumer Healthcare Inc. (PBH) delivered fourth-quarter fiscal 2024 earnings per share (EPS) of $1.02, a 4.7% decline from the year-ago period's figure. The metric also missed the Zacks Consensus Estimate by 10.5%. GAAP EPS for the quarter was 98 cents, a significant improvement from the year-ago loss of $4.78 per share. For the full year, adjusted EPS was $4.21, flat year over year. Revenues Total revenues in the fiscal fourth quarter declined 3.1% year over year (down 2.9% on an organic basis) to ...

Prestige Consumer Healthcare Inc (NYSE:PBH) Q4 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Phil Terpolilli - Director of Investor Relations Ron Lombardi - Chairman, President & CEO Chris Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer Susan Anderson - Canaccord Mitchell Pinheiro - Sturdivant Linda Bolton-Weiser - D.A. Davidson Operator Thank you for standing by. My name is Romainy, and I'll prepare your conference operator today. At this ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______ TO ______ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Inco ...

Prestige Consumer Healthcare (PBH) reported $276.99 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 3.1%. EPS of $1.02 for the same period compares to $1.07 a year ago. View all Key Company Metrics for Prestige Consumer Healthcare here>>> Shares of Prestige Consumer Healthcare have returned +3.5% over the past month versus the Zacks S&P 500 composite's +2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader mark ...

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -10.53%. A quarter ago, it was expected that this medicine distributor would post earnings of $1.04 per share when it actually produced earnings of $1.06, delivering a surprise of 1.92%. Over the last ...

Fourth Fiscal Quarter Ended March 31, 2024 Reported revenues in the fourth quarter of fiscal 2024 of $277.0 million compared to $285.9 million in the fourth quarter of fiscal 2023. Revenues decreased 2.9% excluding the impact of foreign currency. The revenue decline in the quarter was attributable to the inability to supply customer orders late in the quarter in certain brands, the strategic exit of private label revenues, and a lower Women's Health category, partially offset by growth in the International ...

Financial Data and Key Metrics Changes - Net sales for Q3 2024 were $283 million, an increase of nearly 3% compared to the previous year, exceeding expectations [7] - EPS for Q3 was $1.06, up 2% year-over-year, contributing to robust free cash flow of approximately $70 million [9][21] - Year-to-date revenues reached $848.4 million, up 80 basis points, with a 1.2% growth excluding foreign exchange effects [22] Business Line Data and Key Metrics Changes - North American OTC segment revenues were flat year-over-year, with growth in Eye and Ear Care offset by declines in Women's Health and the exit from the private label business [19][23] - International OTC segment revenues increased approximately 20% year-over-year, driven by strong performance from the Hydralyte brand [20][22] Market Data and Key Metrics Changes - The e-commerce channel experienced high single-digit growth year-to-date, now representing about 15% of total sales [64] - The cough and cold category accounts for about 7% of revenue, with Q4 expected to be in line with last year's levels [39] Company Strategy and Development Direction - The company anticipates full-year revenues of $1.135 billion to $1.140 billion, with organic revenue growth of approximately 1% to 2% [32] - The long-term growth strategy aims for 2% to 3% organic growth annually, supported by strong cash flows and potential M&A opportunities [34][36] Management's Comments on Operating Environment and Future Outlook - Management noted heightened business environment uncertainty due to inflation, geopolitical events, and supply chain constraints [6] - The company remains confident in its ability to create shareholder value through cash flow generation and lower leverage [68][90] Other Important Information - The company achieved a leverage ratio of 2.9 times, aligning with its long-term objective of operating below 3 times [28][90] - Management highlighted the importance of maintaining differentiated products to compete against private labels [79] Q&A Session Summary Question: Expectations for the cough and cold category in Q4 - Management expects Q4 sales to be in line with last year's levels, as cough and cold represents about 7% of revenue [39] Question: Thoughts on Women's Health business recovery - Management anticipates recovery and stabilization for Women's Health brands, with expectations for growth next year [40] Question: Initial thoughts for FY '25 guidance - Management suggests starting with a growth expectation of 2% to 3% for top-line growth and mid-single-digit growth for the bottom line [41] Question: Flexibility to invest in the business - Management indicated increased optionality for capital deployment, including M&A and share buybacks, due to reduced leverage [47][68] Question: Performance across the portfolio - Management noted strong performance in Ear & Eye Care and International segments, while non-core brands may see declines [45] Question: Cost savings impact on gross margin - Management has begun to see benefits from cost savings, with gross margin expected to remain flat to slightly up for the year [56] Question: E-commerce performance - E-commerce grew high single digits in Q3, now accounting for about 15% of total sales [64] Question: Market share changes and competitive landscape - Management has not observed any significant share loss to private labels, emphasizing the importance of brand trust [65] Question: M&A strategy and criteria - Management maintains a consistent M&A strategy focused on leading brands with long-term growth potential [67] Question: Discussion on distribution channels - Management indicated that club channels are not a significant focus, while dollar stores have been a growing channel [73][78] Question: Impact of eye drop recalls - Management believes recalls in the eye care category may reinforce the importance of trusted brands like Clear Eyes and TheraTears [80]

leet ENSITIVE This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, diluted EPS, leverage, free cash flow, and organic revenue growth; the Company's ability to execute on its brand-building strategy; the expected market share and consumption trends for the Company's brands; and the Company's ability to reduce debt and execute on ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Ju ...

Prestige Consumer Healthcare Inc. (NYSE:PBH) Q2 2024 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Phil Terpolilli - CFA Ron Lombardi - President and CEO Christine Sacco - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer & Co Susan Anderson - Canaccord Genuity Jon Andersen - William Blair Keonhee Kim - Morningstar Operator Good day, and thank you for standing by. Welcome to the Q2 2024 Prestige Consumer Healthcare Earnings Conference Call. [Operato ...